Alvotech (ALVO)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
ALVO
Alvotech
$5.29
+0.95%
HEALTHCARE · Cap: $1.86B
TAK
Takeda Pharmaceutical Co Ltd ADR
$18.26
+0.83%
HEALTHCARE · Cap: $58.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 933758% more annual revenue ($4.62T vs $494.61M). TAK leads profitability with a -3.5% profit margin vs -36.3%. TAK earns a higher WallStSmart Score of 53/100 (C-).
ALVO
Avoid16
out of 100
Grade: F
TAK
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+72.3%
Fair Value
$17.49
Current Price
$5.29
$12.20 discount
Intrinsic value data unavailable for TAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Generating 73.8B in free cash flow
Large-cap with strong market position
Areas to Watch
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Weak financial health signals
Revenue declined 38.9%
ROE of 2.4% — below average capital efficiency
Earnings declined 9.8%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ALVO
The strongest argument for ALVO centers on Debt/Equity.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.43 suggests the stock is reasonably priced for its growth.
Bear Case : ALVO
The primary concerns for ALVO are Market Cap, Return on Equity, Piotroski F-Score.
Bear Case : TAK
The primary concerns for TAK are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
ALVO carries more volatility with a beta of 0.22 — expect wider price swings.
TAK is growing revenue faster at 10.2% — sustainability is the question.
TAK generates stronger free cash flow (73.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TAK scores higher overall (53/100 vs 16/100) and 10.2% revenue growth. ALVO offers better value entry with a 72.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alvotech
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alvotech Holdings SA, develops and manufactures biosimilars for global markets. The company is headquartered in Iceland.
Visit Website →Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?